Crohn-betegség: vizsgálatok itt: Bulgária
12 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Where
- Burgas, Ruse, Sofia
- Életkor
- 18 év to 85 év
- People
- 385 worldwide
- Run by
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00 - 3. fázisTaking peopleMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Where
- Gorna Oryahovitsa
- Életkor
- 18 év to 70 év
- People
- 290 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00 - 2. fázisTaking peopleA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Where
- Plovdiv, Sliven, Sofia, Sofiya
- Életkor
- 18 év to 75 év
- People
- 268 worldwide
- Run by
- Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Panagyurishte, Plovdiv
- Életkor
- 16 év to 80 év
- People
- 425 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00 - 3. fázisTaking peopleAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Gorna Oryahovitsa, Rousse, Sofia
- Életkor
- 16 év to 80 év
- People
- 980 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184931 - 3. fázisTaking peopleA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Gorna Oryahovitsa, Rousse, Sofia
- Életkor
- 16 év to 80 év
- People
- 751 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184944 - 3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Plovdiv, Sofia, Varna
- Életkor
- 2 év to 17 év
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Burgas, Gorna Oryahovitsa, Plovdiv, Sofia
- Életkor
- 16 év to 80 év
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00 - 3. fázisTaking peopleA Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Where
- Plovdiv, Sofia
- Életkor
- 2 év to 17 év
- People
- 70 worldwide
- Run by
- Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00 - 2. fázisTaking peopleStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Where
- Plovdiv, Sofia, Sofiya, Varna
- Életkor
- 18 év to 75 év
- People
- 590 worldwide
- Run by
- AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00 - 3. fázisTaking peopleA Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Where
- Plovdiv, Sofia
- Életkor
- 2 év to 17 év
- People
- 70 worldwide
- Run by
- Takeda
See details and how to joinNCT06100289 · EU 2023-503188-40-00 - 2. fázisTaking peopleA Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Where
- Plovdiv, Sliven, Sofia, Sofiya
- Életkor
- 18 év to 75 év
- People
- 192 worldwide
- Run by
- Takeda
See details and how to joinNCT06764615 · EU 2024-518914-18-00